VERU logo

Veru (VERU) Stock

Profile

Full Name:

Veru Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

11 February 1999

Indexes:

Not included

Description:

Veru Inc. is a biopharmaceutical company focused on developing innovative medicines for men's and women's health. They work on treatments for prostate cancer, sexual health, and other conditions. Veru aims to improve patient outcomes through research and advanced therapies.

Key Details

Price

$0.58

Annual Revenue

$16.89 M(+3.62% YoY)

Annual EPS

-$0.28(+74.55% YoY)

Annual ROE

-145.40%

Beta

2.19

Events Calendar

Earnings

Next earnings date:

Feb 07, 2025

Recent quarterly earnings:

Aug 08, 2024

Recent annual earnings:

Dec 05, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Apr 28, 2014
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

02 Jan '25 HC Wainwright & Co.
Buy
20 Dec '24 HC Wainwright & Co.
Buy
05 Nov '24 Oppenheimer
Outperform
14 May '24 B. Riley Securities
Buy
13 May '24 HC Wainwright & Co.
Buy
06 May '24 HC Wainwright & Co.
Buy
15 Apr '24 Oppenheimer
Outperform
28 Mar '24 Raymond James
Outperform
08 Feb '24 HC Wainwright & Co.
Buy
27 Sept '23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction
VERU
globenewswire.com27 January 2025

-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% less lean mass than patients receiving WEGOVY alone --

What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now?
What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now?
What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now?
VERU
zacks.com23 January 2025

Does Veru Inc. (VERU) have what it takes to be a top stock pick for momentum investors? Let's find out.

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
VERU
globenewswire.com31 December 2024

MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that it has sold its FC2 Female Condom® (Internal Condom) business to clients managed by Riva Ridge Capital Management LP, a New York City-based investment management firm as well as other co-investors, for $18 million, subject to adjustment as set forth in the purchase agreement.

Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates
Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates
Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates
VERU
zacks.com16 December 2024

Veru Inc. (VERU) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.16 per share a year ago.

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
VERU
globenewswire.com05 November 2024

MIAMI, FL, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas.

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
VERU
globenewswire.com21 October 2024

MIAMI, FL, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at ObesityWeek, taking place November 3-6, 2024, in San Antonio, Texas.

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
VERU
globenewswire.com16 October 2024

MIAMI, FL, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at the World Obesity and Weight Management Congress, taking place October 24-26, 2024, in Baltimore, Maryland.

Veru to Present at the 2024 Cantor Global Healthcare Conference
Veru to Present at the 2024 Cantor Global Healthcare Conference
Veru to Present at the 2024 Cantor Global Healthcare Conference
VERU
globenewswire.com11 September 2024

MIAMI, FL, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present a corporate update with a focus on the progress of Veru's Phase 2b clinical development program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP-1 drugs for weight loss at the 2024 Cantor Global Healthcare Conference on September 18th at 1:55 PM – 2:25 PM Eastern Time.

Veru Inc. (VERU) Q3 2024 Earnings Call Transcript
Veru Inc. (VERU) Q3 2024 Earnings Call Transcript
Veru Inc. (VERU) Q3 2024 Earnings Call Transcript
VERU
seekingalpha.com10 August 2024

Veru Inc. (NASDAQ:VERU ) Q3 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Sam Fisch - Investor Relations & Corporate Communications Mitchell Steiner - Chief Executive Officer Michele Greco - Chief Financial Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Dennis Ding - Jefferies William Wood - B. Riley Securities Gary Nachman - Raymond James Leland Gershell - Oppenheimer Yi Chen - H.C.

Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
VERU
zacks.com08 August 2024

Veru Inc. (VERU) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.13 per share a year ago.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the primary business of Veru?
  • What is the ticker symbol for Veru?
  • Does Veru pay dividends?
  • What sector is Veru in?
  • What industry is Veru in?
  • What country is Veru based in?
  • When did Veru go public?
  • Is Veru in the S&P 500?
  • Is Veru in the NASDAQ 100?
  • Is Veru in the Dow Jones?
  • When was Veru's last earnings report?
  • When does Veru report earnings?
  • Should I buy Veru stock now?

What is the primary business of Veru?

Veru Inc. is a biopharmaceutical company focused on developing innovative medicines for men's and women's health. They work on treatments for prostate cancer, sexual health, and other conditions. Veru aims to improve patient outcomes through research and advanced therapies.

What is the ticker symbol for Veru?

The ticker symbol for Veru is NASDAQ:VERU

Does Veru pay dividends?

No, Veru does not pay dividends

What sector is Veru in?

Veru is in the Healthcare sector

What industry is Veru in?

Veru is in the Biotechnology industry

What country is Veru based in?

Veru is headquartered in United States

When did Veru go public?

Veru's initial public offering (IPO) was on 11 February 1999

Is Veru in the S&P 500?

No, Veru is not included in the S&P 500 index

Is Veru in the NASDAQ 100?

No, Veru is not included in the NASDAQ 100 index

Is Veru in the Dow Jones?

No, Veru is not included in the Dow Jones index

When was Veru's last earnings report?

Veru's most recent earnings report was on 8 August 2024

When does Veru report earnings?

The next expected earnings date for Veru is 7 February 2025

Should I buy Veru stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions